Pfizer's ABRYSVO (RSVpreF) for Respiratory Syncytial Virus

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The

Related Keywords

France ,Spain ,Italy ,Dublin ,Ireland ,Germany ,Japan ,United Kingdom ,United States , ,National Institutes Of Health ,Clinical Development ,Pfizer ,Market Insight ,National Institutes ,Topics Covered ,Marketed Therapies ,Late Stage Emerging Therapies ,Research And Markets ,Rsv Vaccine ,Vaccines ,